Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients - Paul J. Hengeveld; Joyce Schilperoord-Vermeulen; P. Martijn Kolijn; Julie M. N. Dubois; Peter E. Westerweel; Sabina Kersting; Arnon P. Kater; Mark-David Levin; Anton W. Langerak (Blood Cancer Journal, 2025)